Additionally, the stemness marker, CD133, which was significantly upregulated in GBM compared with normal tissues, could well distinguish between different grades of gliomas, while the other upregulated stemness marker, SOX2, was not different for the different grades of glioma. Here, SOX2 is linked to central nervous system cancer.